News & Updates
Filter by Specialty:
Add-on bevacizumab ups hypertension risk in CRC patients
The addition of bevacizumab (BVZ) to the standard regimen for the treatment of advanced colorectal cancer (CRC) appears to increase the risk of cardiovascular events, suggest the results of a meta-analysis presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).
Add-on bevacizumab ups hypertension risk in CRC patients
03 Feb 2023
Saroglitazar may lower cardiovascular risk in NAFLD
Treatment with the dual PPAR α/γ agonist saroglitazar helps improve the serum atherogenic lipoprotein profile in patients with nonalcoholic fatty liver disease (NAFLD), regardless of comorbid conditions and statin use, as shown in a study.
Saroglitazar may lower cardiovascular risk in NAFLD
03 Feb 2023
Prediabetes in youngsters linked to a nearly 80 percent increased risk of CVD
Prediabetes in youngsters is associated with an 88 percent lifetime risk of diabetes and a nearly 80 percent higher risk of cardiovascular disease (CVD), researchers from the Chinese University of Hong Kong (CUHK) have reported.
Prediabetes in youngsters linked to a nearly 80 percent increased risk of CVD
30 Jan 2023
Some antihypertensive medications may lower dementia risk
Use of angiotensin II (ATII)-stimulating antihypertensive medication (AHM), angiotensin receptor blockers (ARBs), and dihydropyridine calcium channel blockers (CCBs) helps reduce the risk of dementia over a decade, but this beneficial effect decreases over time, according to a study.